finance.yahoo.com
Neutralfinance.yahoo.com ·
Needham Raises Price Target Globus
Environment And Natural Resou…EcosystemsForests Rivers OceansAnalyst
Topic context
This topic has been covered 403093 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAnalyst price target adjustments for Globus Medical (GMED) reflect positive Q1 earnings beat and raised EPS guidance. The commercial mechanism is limited to equity valuation sentiment; no direct product/commodity price, supply chain, or margin channel is affected. Impact is single-company-specific, not sector-wide.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Needham raised GMED price target to $117 from $114, Buy rating.
- Wells Fargo lowered GMED price target to $103 from $104, Overweight.
- Q1 EPS $1.12 vs consensus $0.92; revenue $759.85M vs $740.83M.
- FY26 EPS guidance raised to $4.70-$4.80; revenue reaffirmed $3.18B-$3.22B.
- Company focuses on musculoskeletal healthcare solutions and surgical technologies.
Related stories
finance.yahoo.com
Eurodry Edry Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
breitbart.com
Exclusive Senators Moreno and Sheehy Warn Against Planned Spanish Acquisition of Connecticut Bank
fool.com
Canaan Can Q1 2026 Earnings Transcript
fool.com